JP2025503215A - Ntsr1標的化放射性医薬品およびdna損傷応答阻害剤併用療法 - Google Patents

Ntsr1標的化放射性医薬品およびdna損傷応答阻害剤併用療法 Download PDF

Info

Publication number
JP2025503215A
JP2025503215A JP2024544710A JP2024544710A JP2025503215A JP 2025503215 A JP2025503215 A JP 2025503215A JP 2024544710 A JP2024544710 A JP 2024544710A JP 2024544710 A JP2024544710 A JP 2024544710A JP 2025503215 A JP2025503215 A JP 2025503215A
Authority
JP
Japan
Prior art keywords
mammal
group
radiopharmaceutical
alkyl
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503215A5 (cg-RX-API-DMAC10.html
Inventor
ジョン アール. フォーブズ,
サリームラ マハンマド,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fusion Pharmaceuticals Inc
Original Assignee
Fusion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Pharmaceuticals Inc filed Critical Fusion Pharmaceuticals Inc
Publication of JP2025503215A publication Critical patent/JP2025503215A/ja
Publication of JP2025503215A5 publication Critical patent/JP2025503215A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2024544710A 2022-01-28 2023-01-27 Ntsr1標的化放射性医薬品およびdna損傷応答阻害剤併用療法 Pending JP2025503215A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263304178P 2022-01-28 2022-01-28
US63/304,178 2022-01-28
PCT/CA2023/050108 WO2023141717A1 (en) 2022-01-28 2023-01-27 Ntsr1-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy

Publications (2)

Publication Number Publication Date
JP2025503215A true JP2025503215A (ja) 2025-01-30
JP2025503215A5 JP2025503215A5 (cg-RX-API-DMAC10.html) 2026-02-04

Family

ID=87469883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544710A Pending JP2025503215A (ja) 2022-01-28 2023-01-27 Ntsr1標的化放射性医薬品およびdna損傷応答阻害剤併用療法

Country Status (12)

Country Link
US (1) US20250177581A1 (cg-RX-API-DMAC10.html)
EP (1) EP4469092A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025503215A (cg-RX-API-DMAC10.html)
KR (1) KR20240142499A (cg-RX-API-DMAC10.html)
CN (1) CN119136846A (cg-RX-API-DMAC10.html)
AR (1) AR128382A1 (cg-RX-API-DMAC10.html)
AU (1) AU2023211719A1 (cg-RX-API-DMAC10.html)
CA (1) CA3249955A1 (cg-RX-API-DMAC10.html)
IL (1) IL314530A (cg-RX-API-DMAC10.html)
MX (1) MX2024009312A (cg-RX-API-DMAC10.html)
TW (1) TW202337451A (cg-RX-API-DMAC10.html)
WO (1) WO2023141717A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4355325A4 (en) * 2021-06-16 2025-05-07 Fusion Pharmaceuticals Inc. COMBINATION OF A NEUROTENSIN RECEPTOR-BINDING COMPOUND AND FOLFIRINOX

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2478695B1 (es) * 2012-12-20 2015-04-28 Servicio Andaluz De Salud Dispositivo para inducir hipotermia terapéutica
KR20210099073A (ko) * 2018-12-03 2021-08-11 퓨전 파마슈티칼즈 인크. 방사성면역접합체와 체크포인트 억제제의 조합 요법

Also Published As

Publication number Publication date
EP4469092A1 (en) 2024-12-04
TW202337451A (zh) 2023-10-01
MX2024009312A (es) 2024-08-06
US20250177581A1 (en) 2025-06-05
CA3249955A1 (en) 2023-08-03
AU2023211719A1 (en) 2024-08-15
KR20240142499A (ko) 2024-09-30
WO2023141717A1 (en) 2023-08-03
CN119136846A (zh) 2024-12-13
AR128382A1 (es) 2024-04-24
IL314530A (en) 2024-09-01

Similar Documents

Publication Publication Date Title
JP2025013486A (ja) 放射性免疫複合体とdnaの損傷および修復阻害剤の併用療法
JP7693317B2 (ja) 二官能性キレートの薬物動態増強及びその使用
JP7208659B2 (ja) インドリノン化合物の使用
TWI633887B (zh) 用於預防及/或治療多囊性腎臟病之藥物
EA020466B1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
TW202039005A (zh) 新穎之抑制細胞生長的整合素配體綴合物
CN116113406B (zh) Gas41抑制剂及其使用方法
JP2025504558A (ja) Psma標的化放射性医薬品およびチェックポイント阻害剤併用療法
JP2025503213A (ja) Ntsr1標的化放射性医薬品およびチェックポイント阻害剤併用療法
BR112019003973A2 (pt) inibição de atividade olig2
KR20240142499A (ko) Ntsr1-표적화 방사성제약 및 dna 손상 반응 억제제 조합 요법
JP2024521418A (ja) 放射性免疫複合体とチェックポイント阻害剤併用療法
CN121057592A (zh) Psma靶向放射性药物和dna损伤应答抑制剂联合疗法
WO2023164777A1 (en) Gucy2c-targeted radiopharmaceuticals and use thereof
KR20260043111A (ko) 암 치료를 위한 psma 표적 방사성의약품
WO2025255237A1 (en) Use of atr inhibitors in combination with radioligand therapy for the treatment of cancer
HK40060346A (en) Radioimmunoconjugates and dna damage and repair inhibitor combination therapy
TW202448870A (zh) 細胞外HSP90(eHSP90)靶向放射性藥物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260126